BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 11351245)

  • 1. Expression of Fas ligand in gastric carcinoma relates to lymph node metastasis.
    Nagashima H; Mori M; Sadanaga N; Mashino K; Yoshikawa Y; Sugimachi K
    Int J Oncol; 2001 Jun; 18(6):1157-62. PubMed ID: 11351245
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fas-related apoptosis in gastric adenocarcinoma.
    Lim SC
    Oncol Rep; 2003; 10(1):57-63. PubMed ID: 12469145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of Fas and Fas ligand in human gastric adenomas and intestinal-type carcinomas: correlation with proliferation and apoptosis.
    Osaki M; Kase S; Kodani I; Watanabe M; Adachi H; Ito H
    Gastric Cancer; 2001; 4(4):198-205. PubMed ID: 11846063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas.
    Takahama Y; Yamada Y; Emoto K; Fujimoto H; Takayama T; Ueno M; Uchida H; Hirao S; Mizuno T; Nakajima Y
    Gastric Cancer; 2002; 5(2):61-8. PubMed ID: 12111580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fas receptor counterattack against tumor-infiltrating lymphocytes in vivo as a mechanism of immune escape in gastric carcinoma.
    Koyama S; Koike N; Adachi S
    J Cancer Res Clin Oncol; 2001 Jan; 127(1):20-6. PubMed ID: 11206267
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of Fas ligand by human gastric adenocarcinomas: a potential mechanism of immune escape in stomach cancer.
    Bennett MW; O'connell J; O'sullivan GC; Roche D; Brady C; Kelly J; Collins JK; Shanahan F
    Gut; 1999 Feb; 44(2):156-62. PubMed ID: 9895372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fas ligand expression in cervical adenocarcinoma: relevance to lymph node metastasis and tumor progression.
    Kase H; Aoki Y; Tanaka K
    Gynecol Oncol; 2003 Jul; 90(1):70-4. PubMed ID: 12821344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fas (Apo-1/CD95) and Fas ligand interaction between gastric cancer cells and immune cells.
    Lee TB; Min YD; Lim SC; Kim KJ; Jeon HJ; Choi SM; Choi CH
    J Gastroenterol Hepatol; 2002 Jan; 17(1):32-8. PubMed ID: 11895550
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fas ligand expression in esophageal carcinomas and their lymph node metastases.
    Younes M; Schwartz MR; Ertan A; Finnie D; Younes A
    Cancer; 2000 Feb; 88(3):524-8. PubMed ID: 10649242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correlation of Fas/FasL expression to cell apoptosis in Epstein-Barr virus-associated gastric carcinoma.
    He D; Xiao L; Chen JN; Liang Q; Shao CK
    Chin J Cancer; 2010 Mar; 29(3):283-7. PubMed ID: 20193111
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fas ligand expression is correlated with metastasis in colorectal carcinoma.
    Nozoe T; Yasuda M; Honda M; Inutsuka S; Korenaga D
    Oncology; 2003; 65(1):83-8. PubMed ID: 12837986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic significance of Fas and Fas ligand system-associated apoptosis in gastric cancer.
    Ohno S; Tachibana M; Shibakita M; Dhar DK; Yoshimura H; Kinugasa S; Kubota H; Masunaga R; Nagasue N
    Ann Surg Oncol; 2000 Dec; 7(10):750-7. PubMed ID: 11129423
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma.
    Bennett MW; O'Connell J; O'Sullivan GC; Brady C; Roche D; Collins JK; Shanahan F
    J Immunol; 1998 Jun; 160(11):5669-75. PubMed ID: 9605174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Significance of Fas and FasL protein expression in cardiac carcinoma and local lymph node tissues.
    Li Y; Xu DF; Jiang D; Zhao J; Ge JF; Zheng SY
    Int J Clin Exp Pathol; 2015; 8(9):11915-20. PubMed ID: 26617948
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of FasL expression in oral squamous cell cancer.
    Fang L; Sun L; Hu FF; Chen QE
    Asian Pac J Cancer Prev; 2013; 14(1):281-5. PubMed ID: 23534738
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical significance of Fas and FasL protein expression in gastric carcinoma and local lymph node tissues.
    Li Q; Peng J; Li XH; Liu T; Liang QC; Zhang GY
    World J Gastroenterol; 2010 Mar; 16(10):1274-8. PubMed ID: 20222173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of Fas ligand and caspase-3 contributes to formation of immune escape in gastric cancer.
    Zheng HC; Sun JM; Wei ZL; Yang XF; Zhang YC; Xin Y
    World J Gastroenterol; 2003 Jul; 9(7):1415-20. PubMed ID: 12854132
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FAS and FAS-L expression by tumor cells and lymphocytes in breast carcinomas and their lymph node metastases.
    Ioachim HL; Decuseara R; Giancotti F; Dorsett BH
    Pathol Res Pract; 2005; 200(11-12):743-51. PubMed ID: 15792116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fas ligand expression by neoplastic T lymphocytes mediates elimination of CD8+ cytotoxic T lymphocytes in mycosis fungoides: a potential mechanism of tumor immune escape?
    Ni X; Hazarika P; Zhang C; Talpur R; Duvic M
    Clin Cancer Res; 2001 Sep; 7(9):2682-92. PubMed ID: 11555580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fas ligand expression and its correlation with apoptosis and proliferation in Lobund-Wistar prostate carcinomas.
    Gutierrez LS; Noria F; Finol H; Sun L; Castellino F; Pollard M
    Pathobiology; 2005; 72(5):260-8. PubMed ID: 16374070
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.